disappointing preliminary results for a phase three trial of a lung cancer treatment.
AstraZeneca said it slowed progression of the cancer, but the data for overall survival was "not mature" and the results were not statistically significant. The trial will continue to assess overall survival with greater maturity, the company said.
このニュースをすぐに読めるように要約しました。ニュースに興味がある場合は、ここで全文を読むことができます。 続きを読む:
日本 最新ニュース, 日本 見出し
Similar News:他のニュース ソースから収集した、これに似たニュース記事を読むこともできます。
Nio, XPeng stocks surge after EV delivery dataShares of China-based electric-vehicle makers surged Monday, after they reported June deliveries that showed big jumps from May.
続きを読む »
Stocks making the biggest moves in the premarket: Tesla, Apple, AstraZeneca and moreThese are the stocks posting the largest moves in premarket trading.
続きを読む »